{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:31:35Z","timestamp":1775197895079,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-025-01249-1","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:05:46Z","timestamp":1748592346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["\u2018Tranq\u2019: perceptions of xylazine and harm reduction practices among people receiving treatment for substance use disorders"],"prefix":"10.1186","volume":"22","author":[{"given":"Aaron","family":"Salwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KariLynn","family":"Dowling-McClay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Greer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"AlAli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bill","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"8","key":"1249_CR1","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1080\/15563650.2022.2063135","volume":"60","author":"NS Ball","year":"2022","unstructured":"Ball NS, Knable BM, Relich TA, et al. Xylazine poisoning: a systematic review. Clin Toxicol (Phila) Aug. 2022;60(8):892\u2013901. https:\/\/doi.org\/10.1080\/15563650.2022.2063135","journal-title":"Clin Toxicol (Phila) Aug"},{"key":"1249_CR2","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.dadr.2022.100074","volume":"4","author":"MK Reed","year":"2022","unstructured":"Reed MK, Imperato NS, Bowles JM, Salcedo VJ, Guth A, Rising KL. Perspectives of people in Philadelphia who use fentanyl\/heroin adulterated with the animal tranquilizer xylazine; making a case for xylazine test strips. Drug Alcohol Depend Rep Sep. 2022;4:100074. https:\/\/doi.org\/10.1016\/j.dadr.2022.100074","journal-title":"Drug Alcohol Depend Rep Sep"},{"key":"1249_CR3","doi-asserted-by":"publisher","first-page":"109380","DOI":"10.1016\/j.drugalcdep.2022.109380","volume":"1","author":"J Friedman","year":"2022","unstructured":"Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend Apr. 2022;1:233:109380. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109380","journal-title":"Drug Alcohol Depend Apr"},{"key":"1249_CR4","doi-asserted-by":"crossref","unstructured":"Spencer M, Garnett M, Minino A. Drug Overdose Deaths in the United States, 2002\u20132022. 2024.","DOI":"10.15620\/cdc:135849"},{"key":"1249_CR5","unstructured":"CDC NCfHS. Wide-ranging online data for epidemiologic research (WONDER). 2021."},{"key":"1249_CR6","doi-asserted-by":"crossref","unstructured":"Spencer M, Cisewski J, Warner M, Garnett M. Drug Overdose Deaths Involving Xylazine: United States, 2018\u20132021. 2023.","DOI":"10.15620\/cdc:129519"},{"issue":"3","key":"1249_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.drugalcdep.2008.03.005","volume":"2008\u201308\u201301","author":"N Rodr\u00edguez","year":"2008","unstructured":"Rodr\u00edguez N, Vargas Vidot J, Panelli J, Col\u00f3n H, Ritchie B, Yamamura Y. GC\u2013MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles. Drug Alcohol Depend. 2008;2008\u201308\u201301(3):290\u20133. https:\/\/doi.org\/10.1016\/j.drugalcdep.2008.03.005","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"1249_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/nur.0000000000000758","volume":"01","author":"PA O\u2019Malley","year":"2023","unstructured":"O\u2019Malley PA. Rising xylazine drug abuse in humans: A deep and lingering high with wounds, amputations, and death. Clin nurse spec. 2023;01(4):164\u20135. https:\/\/doi.org\/10.1097\/nur.0000000000000758","journal-title":"Jul-Aug"},{"key":"1249_CR9","doi-asserted-by":"crossref","unstructured":"Bedard ML, Murray JG, Huang X-P, et al. Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to Naloxone administration. Cold Spring Harbor Laboratory 2023.","DOI":"10.1101\/2023.09.08.556914"},{"issue":"1","key":"1249_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","volume":"62","author":"JA Giovannitti Jr","year":"2015","unstructured":"Giovannitti JA Jr., Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog Spring. 2015;62(1):31\u20139. https:\/\/doi.org\/10.2344\/0003-3006-62.1.31","journal-title":"Anesth Prog Spring"},{"key":"1249_CR11","unstructured":"Administration SAMHS. Harm Reduction Framework. 2023."},{"issue":"3","key":"1249_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.psc.2022.04.005","volume":"45","author":"A Ramprashad","year":"2022","unstructured":"Ramprashad A, Burnett GM, Welsh C. Harm reduction: not dirty words any more. Psychiatr Clin North Am Sep. 2022;45(3):529\u201346. https:\/\/doi.org\/10.1016\/j.psc.2022.04.005","journal-title":"Psychiatr Clin North Am Sep"},{"key":"1249_CR13","doi-asserted-by":"publisher","first-page":"109425","DOI":"10.1016\/j.drugalcdep.2022.109425","volume":"1","author":"CS Davis","year":"2022","unstructured":"Davis CS, Lieberman AJ, O\u2019Kelley-Bangsberg M. Legality of drug checking equipment in the united States: A systematic legal analysis. Drug Alcohol Depend 2022;1:234:109425. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109425","journal-title":"Drug Alcohol Depend May"},{"issue":"2","key":"1249_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/29767342241265181","volume":"46","author":"S Shrestha","year":"2025","unstructured":"Shrestha S, Cyr K, Hajinazarian G, et al. Exploring xylazine awareness, health impacts, and harm reduction strategies: findings from a multimethods study in Lowell, Massachusetts. Subst Use Addctn J 2025;46(2):291\u2013301. https:\/\/doi.org\/10.1177\/29767342241265181","journal-title":"Subst Use Addctn J Apr"},{"key":"1249_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jsat.2019.07.006","volume":"104","author":"MD Stein","year":"2019","unstructured":"Stein MD, Kenney SR, Anderson BJ, Bailey GL. Perceptions about fentanyl-adulterated heroin and overdose risk reduction behaviors among persons seeking treatment for heroin use. J Subst Abuse Treat 2019;104:144\u20137. https:\/\/doi.org\/10.1016\/j.jsat.2019.07.006","journal-title":"J Subst Abuse Treat Sep"},{"key":"1249_CR16","doi-asserted-by":"publisher","unstructured":"Harrison E, Brant K, Strong-Jones S, Skogseth E, Latkin C, Jones A. Challenges and recommendations for overdose prevention and harm reduction in an era of fentanyl and xylazine: Perspectives of women with opioid use disorder and professionals. Psychology of Addictive Behaviors. 2024-08-22 2024;https:\/\/doi.org\/10.1037\/adb0001021","DOI":"10.1037\/adb0001021"},{"key":"1249_CR17","unstructured":"Becker M. The health belief model and personal health behavior. Health Educ Monogr 1974;324\u2013508."},{"key":"1249_CR18","doi-asserted-by":"crossref","unstructured":"Rosenstock I. Historical origins of the health belief model. Health Education Monographs 1974.","DOI":"10.1177\/109019817400200403"},{"key":"1249_CR19","doi-asserted-by":"publisher","unstructured":"Zewdie A, Mose A, Sahle T et al. The health belief model\u2019s ability to predict COVID-19 preventive behavior: A systematic review. SAGE Open Medicine. 2022-01-01 2022;10:205031212211136. https:\/\/doi.org\/10.1177\/20503121221113668","DOI":"10.1177\/20503121221113668"},{"key":"1249_CR20","doi-asserted-by":"publisher","unstructured":"Rigg KK, Kusiak ES. Perceptions of fentanyl among African Americans who misuse opioids: implications for risk reduction. Harm Reduction Journal. 2023-12-19 2023;20(1)https:\/\/doi.org\/10.1186\/s12954-023-00915-6","DOI":"10.1186\/s12954-023-00915-6"},{"issue":"6","key":"1249_CR21","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1080\/10826084.2018.1555597","volume":"54","author":"CA Latkin","year":"2019","unstructured":"Latkin CA, Dayton L, Davey-Rothwell MA, Tobin KE. Fentanyl and drug overdose: perceptions of Fentanyl risk, overdose risk behaviors, and opportunities for intervention among people who use opioids in Baltimore, USA. Subst Use Misuse. 2019;54(6):998\u20131006. https:\/\/doi.org\/10.1080\/10826084.2018.1555597. 2019-05-12.","journal-title":"Subst Use Misuse"},{"key":"1249_CR22","unstructured":"OneSource P. Sentri7."},{"key":"1249_CR23","doi-asserted-by":"crossref","unstructured":"Spadaro A, O\u2019Connor K, Lakamana S, et al. Self-reported xylazine experiences: A mixed methods study of Reddit subscribers. Cold Spring Harbor Laboratory 2023.","DOI":"10.1101\/2023.03.13.23287215"},{"issue":"2","key":"1249_CR24","doi-asserted-by":"publisher","first-page":"e240572","DOI":"10.1001\/jamanetworkopen.2024.0572","volume":"2024\u201302\u201328","author":"M Hochheimer","year":"2024","unstructured":"Hochheimer M, Strickland JC, Rabinowitz JA, Ellis JD, Dunn KE, Huhn AS. Knowledge, preference, and adverse effects of xylazine among adults in substance use treatment. JAMA Netw Open. 2024;2024\u201302\u201328(2):e240572. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.0572","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1249_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10900-020-00928-3","volume":"46","author":"CB Mistler","year":"2021","unstructured":"Mistler CB, Chandra DK, Copenhaver MM, Wickersham JA, Shrestha R. Engagement in harm reduction strategies after suspected Fentanyl contamination among Opioid-Dependent individuals. J Community Health Apr. 2021;46(2):349\u201357. https:\/\/doi.org\/10.1007\/s10900-020-00928-3","journal-title":"J Community Health Apr"},{"key":"1249_CR26","doi-asserted-by":"publisher","unstructured":"Zibbell JE, Aldridge A, Peiper N, Clarke SED, Rinderle A, Feinberg J. Use of Fentanyl test strips by people who inject drugs: baseline findings from the South Atlantic Fentanyl test strip study (SAFTSS). Int J Drug Policy. 2024\/11\/01\/ 2024;133:104588. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104588","DOI":"10.1016\/j.drugpo.2024.104588"},{"key":"1249_CR27","doi-asserted-by":"publisher","unstructured":"Compton WM, Valentino RJ, Dupont RL. Polysubstance use in the U.S. opioid crisis. Molecular Psychiatry. 2021-01-01 2021;26(1):41\u201350. https:\/\/doi.org\/10.1038\/s41380-020-00949-3","DOI":"10.1038\/s41380-020-00949-3"},{"key":"1249_CR28","doi-asserted-by":"publisher","unstructured":"Michaels NL, Bista S, Short Mejia A, Hays H, Smith GA. Xylazine awareness and attitudes among people who use drugs in Ohio, 2023\u20132024. Harm Reduction Journal. 2024-10-14 2024;21(1)https:\/\/doi.org\/10.1186\/s12954-024-01097-5","DOI":"10.1186\/s12954-024-01097-5"},{"key":"1249_CR29","unstructured":"Administration SAaMHS. National survey of drug use and health. NSDUH) Releases 2021."},{"key":"1249_CR30","doi-asserted-by":"publisher","unstructured":"Rachlis BS, Kerr T, Montaner JS, Wood E. Harm reduction in hospitals: is it time? Harm Reduction Journal. 2009-12-01 2009;6(1):19. https:\/\/doi.org\/10.1186\/1477-7517-6-19","DOI":"10.1186\/1477-7517-6-19"},{"key":"1249_CR31","doi-asserted-by":"publisher","unstructured":"Morgan JR, Wang J, Barocas JA et al. Opioid overdose and inpatient care for substance use disorder care in Massachusetts. Journal of Substance Abuse Treatment. 2020\/05\/01\/ 2020;112:42\u201348. https:\/\/doi.org\/10.1016\/j.jsat.2020.01.017","DOI":"10.1016\/j.jsat.2020.01.017"},{"key":"1249_CR32","doi-asserted-by":"publisher","unstructured":"Frank D, Elliott L, Cleland CM et al. As safe as possible: a qualitative study of opioid withdrawal and risk behavior among people who use illegal opioids. Harm Reduction Journal. 2023-10-27 2023;20(1)https:\/\/doi.org\/10.1186\/s12954-023-00893-9","DOI":"10.1186\/s12954-023-00893-9"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01249-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01249-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:05:49Z","timestamp":1748592349000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01249-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1249"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01249-1","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}